주요메뉴 바로가기
본문 바로가기
하단메뉴 바로가기
통합검색
로그인
고객센터
주요메뉴
질환포커스
세계의약뉴스
국내의약뉴스
성상변경내역
약제급여기준 개정내역
제약업계 소식
메디컬포커스
컨퍼런스
CME
근골격계
남성건강
내분비대사계
면역계
비뇨기계
뇌심혈관계
종양
호흡기계
감각기관계
중추신경계
소화기계
감염계
혈액 및 조혈계
미용
기타
최근 해외학술대회의 주요 발표내용을 제공합니다.
컨퍼런스 커버리지
American Heart Association (AHA) Scientific Sessions 2024
16 Nov - 18 Nov, 2024, United States OLD
Cannabis users at greater risk of heart attack, stroke
2025-01-09
The use of cannabis appears to contribute to a higher risk of myocardial infarction (MI) and stroke, with a similar but rising trend in ischaemic and haemorrhagic stroke, as shown by the results of a study presented at the AHA Scientific Sessions 2024.
Lonely people prone to incident AF due to unhealthy behaviours
2025-01-09
Individuals who are lonely appear to be at an increased risk of incident atrial fibrillation (AF), driven by unhealthy behaviours, suggests a study presented at AHA 2024 Scientific Sessions. In addition, women tend to suffer more from the harmful effects of loneliness.
Mavacamten obviates long-term need for invasive septal reduction therapy in obstructive HCM
2025-01-09
Treatment with the allosteric cardiac myosin inhibitor mavacamten in severely symptomatic patients with obstructive HCM allows for the deferral of invasive SRT for nearly 2.5 years, as shown in the end-of-trial results of VALOR-HCM presented at AHA 2024
Nasal spray form of common diuretic holds promise for managing oedema in HF
2025-01-09
Findings from the RSQ-777-02 trial demonstrate the ability of a novel intranasal formulation of bumetanide, a standard loop diuretic, to reduce tissue swelling caused by heart failure (HF) as effectively as conventional oral and IV formulations.
Obicetrapib cuts LDL-C in patients with HeFH
2025-01-09
Treatment with obicetrapib, a CETP* inhibitor, significantly reduced low-density lipoprotein cholesterol (LDL-C) levels for up to 1 year in patients with heterozygous familial hypercholesterolaemia (HeFH), despite being on maximally tolerated lipid-lowering therapy, according to the BROOKLYN trial presented at AHA 2024.
Pushing BP levels to lower targets better for cardioprotection in T2D
2025-01-09
Intensive systolic blood pressure (BP)-lowering treatment to reach target levels of less than 120 mm Hg is more beneficial than standard treatment in terms of reducing the risk of major cardiovascular events in Chinese patients with type 2 diabetes (T2D) and elevated BP, according to data from the BPROAD* trial.
Sacubitril/valsartan protects against chemo-induced heart damage
2025-01-09
Use of the common heart failure medication sacubitril/valsartan helps reduce cardiotoxicity in high-risk cancer patients undergoing anthracycline therapy, according to the results of the SARAH trial.
Tirzepatide reduces CV death, worsening HF in obese patients with HFpEF
2025-01-09
Treatment with tirzepatide reduced the risk of cardiovascular (CV) death and worsening heart failure (HF) in patients with HF with preserved ejection fraction (HFpEF) and obesity, according to the SUMMIT trial presented at AHA 2024.
TOPSPIN highlights three dual combo pills for BP control
2025-01-09
Three dual combinations of commonly prescribed antihypertensives ? amlodipine and perindopril, perindopril and indapamide, or amlodipine and indapamide ? demonstrated equal blood pressure (BP)-lowering efficacy among Indian adults, according to the results of the TOPSPIN trial presented at AHA 2024.
1
최근 본 콘텐츠
최근 본 콘텐츠가 없습니다
관심제품
관심콘텐츠
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
